Anti-obesity and hypolipidemic effects of fermented Angelica gigas Nakai in a rat model of high-fat diet-induced obesity (Preprint)

Read full text Summarise with VIRAT
Authors: Robert Kim
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

UNSTRUCTURED Background: This experimental study evaluate the effects of Monascus purpureus-fermented Angelica gigas (A. gigas) Nakai (FAG) against body weight gain and visceral fat accumulation, for which we analyzed biochemical markers of obesity and the mRNA expression levels of various genes involved in adipogenesis in a rat model of high-fat diet (HFD)-induced obesity. We also performed an in vitro analysis of the effects of nodakenin isolated from A. gigas on the differentiation of 3T3-L1 pre-adipocytes. Materials and methods: Male Sprague-Dawley (SD) rats were randomly divided into five groups (n=6 per group) according to types of diet: high-fat diet (HFD), HFD+2.5% (w/w) AG, HFD+5% AG, HFD+2.5% FAG and HFD+5% FAG. Then, the effects of nodakenin on the degree of fat accumulation in 3T3-L1 pre-adipocytes were evaluated. Results: After the treatment with the FAG, there was an effect in reducing the body weight gain, visceral fat accumulation and hepatic and serum levels of lipid and leptin. Moreover, there was also a significant decrease in the mRNA expression levels of adipose tissue genes encoding adipocyte protein 2 (aP2), peroxisome proliferator-activated receptor gamma 2 (PPAR γ2) and CCAT/enhancer-binding protein alpha (C/EBP α). Furthermore, nodakenin reduced the fat accumulation in differentiated 3T3-L1 adipocytes in a dose-dependent manner. Conclusions: Monascus purpureus-FAG Nakai ameliorates the HFD-induced obesity; this might arise from its effects in modulating the expressions of multiple genes involved in adipogenesis in the visceral fat tissue of rats. It can therefore be concluded that the FAG might be an ideal candidate to treat the HFD-induced obesity.

Fields of Study & Subjects

Natural Products and Biological Research Pharmacology and Obesity Treatment Adipokines Inflammation and Metabolic Diseases

Publication details

Publication date
28 March 2026
Language
EN
Document type
Preprint